AiCure Stock
AiCure's intelligent medical assistant, IMA, leverages a visual recognition platform to monitor patient progress.
Sign up today and learn more about AiCure Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About AiCure Stock
AiCure's intelligent medical assistant, IMA, leverages a visual recognition platform to monitor patient progress. IMA provides visual dose confirmation, interactive patient support and engagement, and visual diagnostic capabilities. The platform has been validated to improve patient behavior in randomized controlled trials. In clinical research, AiCure is increasing the probability of trial success and introducing more objective clinical endpoints. In population health, AiCure is enabling intelligent decision-making and improving health outcomes. By 2020, there will be a one million nurse shortage in the US. AiCure is striving to help fill this gap. In clinical research, approximately one quarter of clinical trials fail due to a lack of patient oversight, contributing to over $40 billion in annual losses. AiCure is seeking to accelerate better medications into the market.
Funding History
January 2016 | $12.3M |
---|---|
November 2017 | $15.0M |
Management
Chief Product Officer
Michelle Marlborough
Co-Founder & CSO
Laura Shafner
Co-Founder & CEO
Adam Hanina
Press
finance - Feb, 19 2024
AiCure Raises Funds, Secures New Patents, and Bolsters Leadership Teamfinsmes - Jan, 26 2024
AiCure Raises $12M Loan Refinancing And Additional $4M+ From Existing Investorsvcnewsdaily - Jan, 24 2024
AiCure Announces $16M+ Funding Roundprnewswire - Jan, 24 2024
AiCure Raises Funds, Secures New Patents, and Bolsters Leadership Teampharmiweb - Jan, 19 2024
AI-based Clinical Trials Solutions Market Projected to Surge to ...